SCIENTIFIC PROGRAM


MELANOMA BRIDGE 2016
Royal Continental Hotel, SALA AUDITORIUM, Naples, Italy
November 30th - December 3rd, 2016




November 30th 2016

05.30 PM Registration **
06.00 PM Welcome and introduction **
06.30 PM Opening lecture of Melanoma Bridge, Davide Bedognetti
07.00 PM Welcome cocktail **


December 1st 2016

09.00 AM Registration **


Session I - JOINT WITH SITC Evolving Topics in Cancer Immunotherapy
Coordinators: Paolo A. Ascierto, Sandra Demaria, Giuseppe Masucci, Magdalena Thurin

09.30 AM Treatment-induced molecular pathways regulate the immunogenicity of radiotherapy, Sandra Demaria
09.50 AM In situ tumor vaccination using local radiotherapy and intratumoral immunocytokine, Paul Sondel
10.10 AM Cancer vaccines in the era of checkpoint blockade, Willem W. Overwijk
10.30 AM Therapy of solid cancers using T cells and running shoes, Per thor Straten
10.50 AM Break **
11.05 AM Discussion on the best research studies on Evolving Topics in Cancer Immunotherapy **
12.05 PM Symposium: "Evolving Topics in Cancer Immunotherapy: Combination"
01.05 PM Conclusions, Paolo A. Ascierto, Sandra Demaria, Giuseppe Masucci, Magdalena Thurin
01.20 PM Lunch **
02.20 PM Symposium: "Merkel Cell Carcinoma and Cancer Immunotherapy"


Session II - World-Wide Immunoscore Task Force
Chairpersons: Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola

03.20 PM Immunoscore worldwide consortium and beyond, Jerome Galon
03.40 PM Immunoprofiling in Melanoma, Paolo A. Ascierto
04.00 PM Implementation of the Immunoscore in a Pathology Lab based on the LEAN Management System, Alessandro Lugli
04.20 PM Break **
04.35 PM Suppressive Index: the other side of the Immunoscore?, Carlo Bifulco
04.55 PM The immunoscore beyond cancer, Franck Pages
05.15 PM Immmunoscore and other prognostic factors in the personalized cancer treatment's scenario, Giuseppe Masucci
05.35 PM Discussion
05.55 PM Conclusions, Paolo A. Ascierto, Jerome Galon, Francesco M. Marincola


December 2nd 2016
Session III - System biology Session: Molecular
Chairpersons: Luigi Buonaguro, Ena Wang

09.30 AM microRNAs regulate resistance to target therapy in melanoma, Gennaro Ciliberto
09.50 AM Melanoma Mutations and Precision Medicine, Ruth Halaban
10.10 AM Resistance to MAPK and checkpoint targeted therapy, Roger Lo
10.30 AM Biomarkers for treatment decision, Reinhard Dummer
10.50 AM Break **
11.05 AM Discussion on the best research studies on System biology Session: Molecular **
12.05 PM Symposium: Bringing overall survival in BRAF + MM Patiens: the combined inhibition of Braf & Mek
01.05 PM Conclusions, Luigi Buonaguro, Ena Wang
01.20 PM Lunch **


Session IV - Combination Strategy Session
Chairpersons: Nicola Mozzillo, Giuseppe Palmieri

02.20 PM Symposium: "Raising the bar: combining evidence and practice to improve outcomes in BRAF mutated metastatic melanoma patients" **
03.20 PM Overcoming radiation-induced barriers to an immune response, Silvia C. Formenti
03.40 PM Where are we really with clinical trials of combination immunotherapy? Michael Postow
04.00 PM Combining checkpoint inhibitors, Igor Puzanov
04.20 PM Innovative combination strategies - oncolytic therapy and systemic immunotherapy approaches, Sanjiv Agarwala
04.40 PM Break **
04.55 PM Discussion on the best research studies on Combination strategy **
05.55 PM Conclusions, Nicola Mozzillo, Giuseppe Palmieri
06.30 PM Melanoma Bridge Award **, Paolo A. Ascierto, Francesco M. Marincola, Nicola Mozzillo


December 3rd 2016
Session V - System biology Session: Immunology
Chairpersons: Alexander Eggermont, Giuseppe Masucci

09.10 AM Rational design of combination immunotherapy, Samir Khleif
09.30 AM Bioinformatic approaches to investigate mechanisms driving the non-T cell-inflamed tumor microenvironment, Jason Luke
09.50 AM Gut microbiome bridging systemic and anticancer immunity, Connie Duong, Laurence Zitvogel
10.10 AM Next Targets for Immune Checkpoint Blockade, Hassane Zarour
10.30 AM Advances in Dendritic Cell Cancer Immunotherapy Therapy, David Stroncek
10.50 AM Break **
11.05 AM Discussion on the best research studies on System biology Session: Immunology **
12.05 AM Symposium | Immuno-oncology: a revolution in the treatment strategy of advanced melanoma **
01.05 PM Conclusions, Alexander Eggermont, Giuseppe Masucci
01.20 PM Lunch **


Session VI - Biomarkers Session
Chairpersons: Gerardo Botti, Alessandro Testori

02.20 PM The promising alliance of electrochemotherapy and immunotherapy, Lluis Mir
03.00 PM CSPG4 as a target of antibody-based immunotherapy, Soldano Ferrone
03.20 PM Prognostic and predictive markers for patients treated with CTLA-4 and PD-1 inhibitors, Claus Garbe
03.40 PM Update on PD-L1 and related markers, Janis Taube
04.00 PM Break **
04.15 PM Understanding mechanisms of response and resistance to melanoma therapy: lessons learned from mouse and man, Jennifer Wargo
04.35 PM Discussion on the best research studies on Biomarkers Session **
05.35 PM Conclusions, Gerardo Botti, Alessandro Testori




ORAL COMMUNICATIONS





December 1st 2016
SESSION I - JOINT WITH SITC Evolving topics in cancer immunotherapy
Coordinators: Paolo A. Ascierto, Sandra Demaria, Giuseppe Masucci, Magdalena Thurin

11.05 AM Discussion on the best research studies on Evolving Topics in Cancer Immunotherapy **
11.05 AM Altering the gut microbiota to improve responses to immune checkpoint blockade
Connie Duong, Marie Vetizou, Laurence Zitvogel
11.25 AM PD-L1 expression as a biomarker for nivolumab plus ipilimumab and nivolumab alone in advanced melanoma: A pooled analysis
Georgina V. Long, James Larkin, Paolo A. Ascierto, F. Stephen Hodi, Piotr Rutkowski, Vanna Chiarion-Sileni, Jessica Hassel, Céleste Lebbé, Anna Pavlick, John Wagstaff, Dirk Schadendorf, Reinhard Dummer, David Hogg, John B.A.G. Haanen, Pippa Corrie, Christoph Hoeller, Christine Horak, Jedd D. Wolchok, Caroline Robert
11.45 AM Safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma
Mario Sznol, Pier Francesco Ferrucci, David Hogg, Michael B. Atkins, Pascal Wolter, Massimo Guidoboni, Céleste Lebbé, John Kirkwood, Jacob Schachter, Gregory A. Daniels, Jessica Hassel, Jonathan Cebon, Winald Gerritsen, Victoria Atkinson, Luc Thomas, John Mccaffrey, Derek Power, Joel Jiang, F. Stephen Hodi, Jedd D. Wolchok J


December 2nd 2016
SESSION III - System biology session: molecular
Chairpersons: Luigi Buonaguro, Ena Wang

11.05 AM Discussion on the best research studies on system biology: molecular **
11.05 AM Inhibition of Stearoyl-Coa desaturase 1 (SCD1) enzymatic activity reverts BRAFi and MEKi –induced selection of cancer stem cells in BRAF-mutated malignant melanoma
Maria Elena Pisanu, Alessia Noto, Luigi Fattore, Debora Malpicci, Gennaro Ciliberto, Rita Mancini
11.35 AM Screening of malignant melanoma (MM) by miRNA: preliminary data on incidence after initial clinical evaluation
Marcella Occelli, Carolina Cauchi, Grazia Sciancalepore, Cristiana Lo Nigro, Michela Rovera, Chiara Varamo, Daniela Vivenza, Zelda Seia, Stefania Palazzini, Fabiana Errico, Davide Basso, Laura Quaranta, Giuseppe Forte, Fulvio Lavagna, Silvia Violante, Paolo Bosio, Laura Lattanzio, Marco Carlo Merlano


SESSION IV - Combination strategy session
Chairpersons: Nicola Mozzillo, Giuseppe Palmieri

04.55 PM Discussion on the best research studies on combination strategy **
4.55 PM Efficacy of long-term cobimetinib (C) plus vemurafenib (V) in advanced BRAFV600-mutated melanoma: 3-year follow-up of the phase 3 coBRIM study and 4-year follow-up of the phase 1b BRIM7 study
Paolo A. Ascierto, Grant A McArthur, Brigitte Dréno, Victoria Atkinson, James Larkin, Adil Daud, Anna Pavlick, Rene Gonzalez, Karl D Lewis, Omid Hamid, Thomas Gajewski, Igor Puzanov, Jessie Hsu, Erica Park, Antoni Ribas
05.15 PM Results of COLUMBUS part 1: a phase 3 study of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in BRAF-mutant melanoma
Helen J. Gogas, Reinhard Dummer, Paolo A. Ascierto, Ana Arance, Mario Mandala, Gabriella Liszkay, Claus Garbe, Dirk Schadendorf, Ivana Krajsova, Ralf Gutzmer, Vanna Chiarion Sileni, Caroline Dutriaux, Jan Willem B. de Groot, Naoya Yamazaki, Carmen Loquai, Laure A., Moutouh-de Parseval, Michael D. Pickard, Victor Sandor, Caroline Robert, Keith T. Flaherty
05.35 PM Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma
Markus V. Heppt, Thomas K. Eigentler, Katharina C. Kähler, Rudolf A. Herbst, Daniela Göppner, Thilo Gambichler, Jens Ulrich, Edgar Dippel, Carmen Loquai, Beatrice Schell, Bastian Schilling, Susanne G. Schäd, Erwin S. Schultz, Fanny Matheis, Julia K. Tietze, Carola Berking


December 3rd 2016
SESSION V - System biology session: immunology
Chairpersons: Alexander Eggermont, Giuseppe Masucci

11.05 AM Discussion on the best research studies on system biology: immunology **
11.05 AM Regulation of T cell sensitivity by TCR-proximal signaling components during anti-melanoma responses
Duane Moogk, Shi Zhong, Zhiya Yu, Ivan Liadi, William Rittase, Victoria Fang, Janna Dougherty, Arianne Perez-Garcia, Iman Osman, Cheng Zhu, Navin Varadarajan, Nicholas P. Restifo, Alan Frey, Michelle Krogsgaard
11.35 AM Electrochemotherapy induces T regulatory cells decrease and cytotoxic T cells recruitment in treated Melanoma Metastases
Gianni Gerlini, Paola Di Gennaro, Carmelo Urso, Serena Sestini, Paola Brandani, Nicola Pimpinelli, Lorenzo Borgognoni


SESSION VI - Biomakers session
Chairpersons: Gerardo Botti, Alessandro Testori

04.35 PM Discussion on the best research studies on biomarkers **
04.35 PM Biomarkers Tumor-infiltrating immune cells as potential predictive markers of response to treatment and survival in metastatic melanoma patients receiving ipilimumab
Timea Balatoni, Anita Mohos, Timea Sebestyén, Anita Varga, Judit Oláh, Zsuzsanna Lengyel, Gabriella Emri, Gabriella Liszkay G, Andrea Ladányi
04.55 PM Identification of five circulating microRNAs with high dignostic values in cutaneous melanoma
Beatrice Polini, Sara Carpi, Barbara Pardini, Alessio Naccarati, Stefano Fogli, Maria Cristina Breschi, Antonella Romanini, Paola Nieri
05.15 PM Impact of Phosphoinositide 3 Kinase and Vitamin D3 Nuclear Receptor Single Nucleotide Polymorphisms On The Outcome Of Malignant Melanoma Patients
Francesca Morgese, Davide Soldato, Silvia Pagliaretta, Riccardo Giampieri, Donatella Brancorsini, Silvia Rinaldi, Mariangela Torniai, Anna Campanati, Giulia Ganzetti, Annamaria Offidani, Alfredo Giacchetti, Giuseppe Ricotti, Agnese Savini, Azzurra Onofri, Francesca Bianchi, Rossana Berardi






POSTER SESSIONS



P01 A "special" patient Giovanna Galdo, Gianfranco Orlandino, Salvatore Serio, Domenico Massariello, Tommaso Fabrizio
P02 Nivolumab and Diabetes Mellitus: Safe Administration in a Patient with Pancreatic Metastases from Melanoma Elisabetta Gambale, Camilla Tinari, Alberto Quinzii, Alessio Cortellini, Consiglia Carella, Michele De Tursi
P03 Adverse events associated with "Anti-programmed death-1" therapy for patients with melanoma Adele Emanuela De Francesco, Mariarosanna De Fina, Maria Cristina Zito, Maria Dezia Bisceglia, Stefania Esposito
P04 The A2B adenosine receptor: an emerging therapeutic target in cancer Silvana Morello, Claudia Sorrentino, Aldo Pinto
P05 CTLA4-blocking antibodies induced a different entity of severe hypophysitis in patients with advanced melanoma: experience of a multidisciplinary team for a better clinical management Antonella Di Sarno, Antonella Bianco, Carmine D'Aniello, Francesca Andreozzi, Lucia Festina, Vito Vanella, Paolo Antonio Ascierto, Vincenzo Montesarchio
P06 Human antibody fragments revealed unique sialylation pattern on cancer stem cells in melanomas and were used for chimeric antigenic receptor constructs to genetically engineer immune T cells Beatrix Kotlan, Maria Godeny, Farkas Emil, Laszlo Toth, Szabolcs Horvath, Klara Eles, Timea Balatoni, Akos Savolt, Andras Szollar, Miklós Kasler, Gabriella Liszkay
P07 Cutaneous melanoma microenvironment: a two-dimensional topographical computer-aided analysis as a perspective for new therapeutic strategies Daniel Yiu, Fabio Grizzi, Federica Patrinicola, Maurizio Chiriva-Internati, Stefania Motta, Marcello Monti
P08 Myeloid Derived Suppressor Cells (MDSC) monitoring in melanoma patients reated with immunotherapy Lavinia Benini, Stefano Ugel, Sara Cingarlini, Alessandra Fiore, Elisabetta Grego, Giampaolo Tortora, Vincenzo Bronte, Luca Tondulli
P09 Prognostic value of sentinel lymph node tumor burden measurement in melanoma patients Gianluca Di Monta, Corrado Caracò, Ugo Marone, Lucia Festino, Paolo A. Ascierto, Nicola Mozzillo


* To be confirmed
** Not included in the CME accredited program

For information please contact info@melanomabridge.org